XTL BIOPHARMACEUTICALS LTD

XTL Biopharmaceuticals Ltd. is a company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases, and has expanded into the data collection industry. The company was established as a private company limited by shares under the laws of the State of Israel on March 9, 1993, under the name Xenograft Technologies Ltd. It re-registered as a public company on June 7, 1993, in Israel, and changed its name to XTL Biopharmaceuticals Ltd. on July 3, 1995. XTL commenced operations to use and commercialize technology developed at the Weizmann Institute, in Rehovot, Israel. Since 1993, the company has pursued therapeutic and pharmaceutical development programs for the treatment of a variety of indications including hepatitis B, hepatitis C, diabetic neuropathic pain, schizophrenia, SLE, and multiple myeloma, most of which have terminated. In August 2024, XTL completed the acquisition of 100% of the share capital of The Social Proxy Ltd., an AI web data company. The Social Proxy develops, operates, and distributes a unique ethical, Internet Protocol based proxy data extraction platform for AI and for Business Intelligence purposes at scale. XTL currently has two subsidiaries: The Social Proxy Ltd., and Xtepo Ltd., a private company limited by shares under the laws of the State of Israel, which holds a license for the exclusive use of rHuEPO for the treatment of multiple myeloma.